



INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Complete if Known

Application Number 10/736,640
Filing Date December 17, 2003
First Named Inventor Don J. DIAMOND
Group Art Unit 1648
Examiner Name To Be Assigned

Sheet 1 of 4 Attorney Docket Number 1954-437

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code (if known)		
AJ	AA	6,074,645		Diamond et al.	06-13-2000
	AB	5,736,142		Sette et al.	04-07-1998
	AC	4,716,104		Harris et al.	12-29-1987
	AD	4,762,780		Spector et al.	08-09-1988
	AE	5,635,363		Altman et al.	06-03-1997

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patentee of Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T ⁶
		Office	Number	Kind Code (if known)			
AF	AF	PCT	WO 94/00150	A1	City of Hope	01-06-1994	
AG	AG	PCT	WO 00/75180	A2	Hans-Dieter VOLK et al.	12-14-2000	AB
AH	AH	PCT	WO 98/26074	A1	Institut National de la Sante et de la Recherche Medicale	06-18-1998	AB
AI	AI	PCT	WO 97/40165	A1	The Wistar Institute of Anatomy and Biology	10-30-1997	
AJ	AJ	PCT	WO 99/19349	A1	City of Hope	04-22-1999	

Examiner
Signature

Date
Considered

8/21/06

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code.

⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached. AB Indicates that only an English language abstract is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Complete if Known	
				Application Number	10/736,640
				Filing Date	December 17, 2003
				First Named Inventor	Don J. DIAMOND
				Group Art Unit	1648
				Examiner Name	To Be Assigned
Sheet	2	of	4	Attorney Docket Number	1954-437
OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published			T ⁶
AJ	AK	Alexander et al., "Development of High Potency Universal DR-Restricted Helper Epitopes by Modification of High Affinity DR-Blocking Peptides," <u>Immunity</u> 1:751-761, December 1994.			
	AL	Bernhard et al., "Cytotoxic T Lymphocytes from HLA-A2 Transgenic Mice Specific for HLA-A2 Expressed on Human Cells," <u>J. Exp. Med.</u> 168:1157-1162, September 1988.			
	AM	Berzofsky et al., "Construction of peptides Encompassing Multideterminant Clusters of Human Immunodeficiency Virus Envelope to Induce in Vitro T Cell Responses in Mice and Humans of Multiple MHC Types," <u>The J. of Clinical Investigation</u> 88:876-884, September 1991.			
	AN	Boppana et al., "Recognition of Human Cytomegalovirus Gene Products by HCMV-specific Cytotoxic T Cells," <u>Virology</u> 222:293-296, 1996.			
	AO	Borysiewicz et al., "Relative Frequency of Stage-specific CTL Recognizing the 72-kD Immediate Early Protein and Glycoprotein B Expressed by Recombinant Vaccinia Viruses," <u>J. Exp. Med.</u> 168:919-931, September 1988.			
	AP	Brouwenstijn et al., "Definition of Unique and Shared T-Cell Defined Tumor Antigens in Human Renal Cell Carcinoma," <u>J. of Immunotherapy</u> 21(6):427-434, 1998.			
	AQ	Chujoh et al., "The role of anchor residues in the binding of peptides to HLA-A*1101 molecules," <u>Tissue Antigens</u> 52:501-509, 1998.			
	AR	Clay et al., "Changes in the Fine Specificity of gp100 ₍₂₀₉₋₂₁₇₎ -Reactive T Cells in Patients Following Vaccination with a Peptide Modified at an HLA-A2.1 Anchor Residue," <u>J. of Immunology</u> 162:1749-1755, 1999.			
	AS	Greenberg et al. "Development of a treatment regimen for human cytomegalovirus (CMV) infection in bone marrow transplantatoin recipients by adoptive transfer of donor-derived CMV-specific T cell clones expanded <i>in vitro</i> " in: <u>Annals of the New York Academy of Sciences</u> (Antigen and Clone-Specific Immunoregulation) 636:184-195, 1991.			
	AT	Gyulai et al., "Cytotoxic T Lymphocyte (CTL) Responses to Human Cytomegalovirus pp65, IE1-Exon4, gB, pp150, and pp28 in Healthy Individuals: Reevaluation of Prevalence of IE1-Specific CTLs," <u>The J. of Infectious Diseases</u> 181:1537-46, 2000.			
	AU	Ishioka et al. "Utilization of MHC Class I transgenic mice for development of minigen DNA vaccines encoding multiple HLA-restricted CTL epitopes," <u>J. Immunology</u> 162:3915-3925, 1999.			
Examiner Signature				Date Considered	8/21/06


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Complete if Known	
				Application Number	10/736,640
				Filing Date	December 17, 2003
				First Named Inventor	Don J. DIAMOND
				Group Art Unit	1648
				Examiner Name	To Be Assigned
Sheet	3	of	4	Attorney Docket Number	1954-437
OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published			T ⁶
AJ	AV	Kern et al., "Analysis of CD8 T cell reactivity to cytomegalovirus using protein-spanning pools of overlapping pentadecapeptides," <u>Eur. J. Immunol.</u> 30:1676-1682, 2000.			
	AW	Kern et al., "Target Structures of the CD8 ⁺ -T Cell Response to Human Cytomegalovirus: the 72 Kilodalton Major Immediate-Early Protein Revisited," <u>J. of Virology</u> 73(10):8179-8184, Oct. 1999.			
	AX	Lipford et al. "Peptide Engineering Allows Cytotoxic T-cell Vaccination Against Human Papilloma Virus Tumour Antigen, E6," <u>Immunology</u> 84:298-303, 1995.			
	AY	Livingston et al. "Altered helper T lymphocyte function associated with chronic hepatitis B virus infection and its role in response to therapeutic vaccination in humans," <u>J. Immunology</u> 162:3088-3095, 1999.			
	AZ	Ohlin et al. "Characterization of human monoclonal antibodies directed against the pp65-kD matrix antigen of human cytomegalovirus," <u>Clin. Exp. Immunol.</u> 84:508-514, 1991.			
	BA	Oseroff et al. "Pools of lipidated HTL-CTL constructs prime for multiple HBV and HCV CTL eiptope responses," <u>Vaccine</u> 16(8):823-833, 1998.			
	BB	Panina-Bordignon et al., "Universally immunogenic T cell epitopes: promiscuous binding to human MHC class II and promiscuous recognition by T cells," <u>Eur. J. Immunol.</u> 19:2237-2242, 1989.			
	BC	Retière et al., "Generation of Cytomegalovirus-Specific Human T-Lymphocyte Clones by Using Autologous B-Lymphoblastoid Cells with Stable Expression of pp65 or IE1 Proteins: a Tool to Study the Fine Specificity of the Antiviral Response," <u>J. of Virology</u> 74(9):3948-3952, May 2000.			
	BD	Riddell et al. "Class I MHC-restricted cytotoxic T lymphocyte recognition of cells infected with human cytomegalovirus does not require endogenous viral gene expression," <u>J. Immunology</u> 146(8):2795-2804, April 15, 1991.			
	BE	Rüger et al. "Primary structure and transcription of the genes coding for the two virion phosphoproteins pp65 and pp71 of human cytomegalovirus," <u>J. Virology</u> 61(2):446-453 February 1987.			
	BF	Schild et al., "Efficiency of peptides and lipopeptides for in vivo priming of virus-specific cytotoxic T cells," <u>Eur. J. Immunol.</u> 21:2649-2654, 1991.			
	BG	Theobald et al., "Targeting p53 as a general tumor antigen," <u>Proc. Natl. Acad. Sci. USA</u> 92:11993-11997, December 1995.			
	BH	Tsunoda et al. "Lipopeptide particles as the immunologically active component of CTL inducing vaccines," <u>Vaccine</u> 17:675-685, 1999.			
✓	BI	Vierboom et al. "Peptide Vaccination with an Anchor-Replaced CTL Epitope Protects Against Human Papillomavirus Type 16-Induced Tumors Expressing the Wild-Type Epitope," <u>J. Immunotherapy</u> 21(6):399-408, 1998.			
Examiner Signature				Date Considered	8/21/06

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Complete if Known	
				Application Number	10/736,640
				Filing Date	December 17, 2003
				First Named Inventor	Don J. DIAMOND
				Group Art Unit	1648
				Examiner Name	To Be Assigned
Sheet	4	of	4	Attorney Docket Number	1954-437
OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published			T ⁶
AJ	BJ	Wentworth et al., "Differences and similarities in the A2.1-restricted cytotoxic T cell repertoire in humans and human leukocyte antigen-transgenic mice," <u>Eur. J. Immunol.</u> 26:97-101, 1996.			
	BK	Wentworth et al. "In Vitro induction of Primary, Antigen-Specific CTL from Human Peripheral Blood Mononuclear Cells Stimulated with Synthetic Peptides," <u>Molecular Immunology</u> 32(9):603-612, 1995.			
	BL	Moldoveanu, Zina, et al., "CpG DNA, a Novel Immune Enhancer for Systemic and Mucosal Immunization With Influenza Virus," <u>Vaccine</u> 16(11/12):1216-1224, 1998.			
	BM	Vitiello et al., "Development of a lipopeptide-based therapeutic vaccine to treat chronic HBV infection," <u>J. Clin. Invest.</u> , 95:341-349, 1995.			
	BN	Altman et al., "Phenotypic Analysis of Antigen-Specific T Lymphocytes," <u>Science</u> , 274:94-96, 1996.			
	BO	Crawford et al., "Detection of Antigen-Specific T Cells with Multivalent Soluble Class II MHC Covalent Peptide Complexes," <u>Immun.</u> , 8:675-682, 1998.			
	BP	Liu et al., "Detection of glutamic acid decarboxylase-activated T cells with I-A ⁹⁷ tetramers," <u>PNAS Early Edition</u> , 1-6 (www.pnas.org) October 16, 2000.			
	BQ	Gillespie et al., "Functional Heterogeneity and High Frequencies of Cytomegalovirus-Specific CD8+ T Lymphocytes in Healthy Seropositive Donors," <u>Journal of Virology</u> 74(17):8140-8150, 2000.			
	BR	Appay et al., "HIV-specific CD8+ T Cells Produce Antiviral Cytokines but Are Impaired in Cytolytic Function," <u>J. Exp. Med.</u> , 192:1, 63-75, 2000.			
	BS	Shacklett et al., "Isolation of Cytomegalovirus-Specific Cytotoid T-Lymphocytes from Gut-Associated Lymphoid Tissue (GALT) of HIV Type 1-Infected Subjects", <u>Aids Research and Human Retroviruses</u> , 16:12, 1157-1162, 2000.			
	BT	"Use Of A CMV pp65-Specific HLA Tetramer to Select and Expand CMV-Specific CD8+ CTL," <u>The Journal of the American Society of Hematology</u> 94:10, 155a, Nov. 15, 1999 (Abstract).			
	BU	Zaia et al., "Status of Cytomegalovirus Prevention and Treatment in 2000," <u>American Society of Hematology</u> 339-355, 2000.			
	BV	Spaete et al., "Human Cytomegalovirus Strain Towne Glycoprotein B is Processed by Proteolytic Cleavage," <u>Virology</u> 167:207-225, 1988.			
✓	BW	Pande et al. "Cloning and Physical Mapping of a Gene Fragment Coding for a 64-Kilodalton Major Late Antigen of Human Cytomegalovirus," <u>PNAS USA</u> , 81:4965-4969, 1984.			
Examiner Signature				Date Considered	8/21/06

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.